Atomoxetine: A selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder

Christopher J. Kratochvil, Brigette S. Vaughan, Martin J. Harrington, William J. Burke

Research output: Contribution to journalArticle

69 Scopus citations


Atomoxetine (Strattera™, Eli Lilly & Co.) is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). So far, two open-label and seven randomised, double-blind, placebo-controlled, clinical trials have been published, six in youths and three in adults. Each of these trials has shown a positive response as measured by the primary efficacy measures, the ADHD-IV Rating Scale (ADHD RS) or the Conners Adult ADHD Rating Scale (CAARS). Atomoxetine has generally been well tolerated. In November of 2002 the FDA approved atomoxetine for use in the US for the treatment of ADHD in children, adolescents and adults. Atomoxetine is the first nonstimulant approved by the FDA for the treatment of ADHD and the first medication approved for the treatment of adult ADHD.

Original languageEnglish (US)
Pages (from-to)1165-1174
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Issue number7
StatePublished - Jul 1 2003



  • Atomoxetin
  • Attention-deficit/hyperactivity disorder
  • Nonstimulant
  • Noradrenaline

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this